PharmX Technologies Ltd (ASX: PHX) Share Price and News

Mr Bastas has experience developing and operating businesses across pharmaceuticals, consumer health and pharmacy retailing and wholesaling. He is currently the Executive Chairman and CEO of DBG Health, Australia's pharmaceutical, health and beauty products business. In 2015 Dennis acquired the Arrow Pharmaceuticals business from Aspen and in 2019 he merged the business with Apotex Australia to form Arrotex Pharmaceuticals. In 2023 Dennis acquired full ownership of Arrotex Pharmaceuticals, Juno Pharmaceuticals and Axe Health to form DBG Health. In 2003 Dennis founded Ascent Pharmaceuticals and as CEO went on to build his generic pharmaceutical company which was sold to Actavis Pharmaceuticals in 2012. Dennis was also the shareholder and Chairman of the Central Healthcare group of companies which he developed in 2010 and which included CHS, a pharmacy wholesaling business, and PharmaSave, a retail pharmacy group. Dennis went on to sell the Central Healthcare group of companies to Sigma Pharmaceuticals in 2014. Dennis is also currently the founder and Executive Chairman of myDNA - a pharmacogenomic and health genomic platform company.

Ms Shaw, on arrival in Australia became Director of Nursing and Chief Executive Officer of two private hospitals. Founding an international healthcare consulting business, which was later acquired by Healthsouth, she co-founded Vision Group, which became an ASX-listed Ophthalmic Doctor equity model. She has founded and lead healthcare companies which have either been sold or listed on the ASX and has worked on international mergers and acquisitions with private equity companies in the UK, Australia and the USA. Currently she co-owns Sydney Breast Clinic and holds existing board positions at Magentus, Ellerston JAADEAustralian PrivateAssets Fund, Mabie Technologies, PharmX and Prospection. Jayne also serves as a Non-Executive Director at Pinnacle Charitable Foundation. Other current listed directorships: BCAL Diagnostics Limited. Former listed directorships (last 3 years): The Citadel Group (Jayne is still a director, but the company is no longer listed). She is chair of the Risk Committee.

Mr Newbery has over 35 years of experience in executive and Board roles for ASX listed companies operating in the technology, telecommunications, urban services and facilities management sectors. Jon is currently Interim CFO of PharmX while Zoe Hillier is on maternity leave. He is also Chairman of Repurpose It Pty Ltd, a Victorian based business focused on the recycling of construction and demolition materials and organics and a Non executive director of Linen Services Australia, the commercial laundry business operating in Australia. Previously Jon held roles as Head of Corporate Finance (M&A) at Downer EDI Limited, Australia's leading urban services and facilities management provider, the Chief Executive Officer of ASX listed Clarity OSS Limited which developed operational support systems for telecommunication operators across the globe and as Chairman of UK based banknote trading system developer IMX Software. Primary areas of expertise include mergers and acquisitions, corporate finance, financial and strategic planning and the implementation and oversight of reporting and corporate governance structures.

Mr England has over 35 years of experience and global relationships formed through his consulting and senior management roles in Australia, the UK and Europe. He held management roles with the global health and beauty companyAlliance UniChem PLC (nowWalgreens Boots Alliance), which operates 13,000 pharmacies and distributes across 11 countries. As Group Director for Alliance UniChem, Nick was responsible for merger, acquisition and service agreement opportunities with key global network partners. Previously, Nick was also CEO of Alliance UniChem Retail International with responsibility for 300 pharmacies across Europe. He is currently a Principal ofSydney-based international retail pharmacy consultancy IQ Consulting. He is member of Risk Committee.

Mr Mellis career has seen him develop and manage consumer health brands, and consumer goods markets in Australia, New Zealand, UK, US and more recently Europe. His 25 years in the industry has provided Sandy with experience in managing large multi-disciplinary teams, across a variety of market channels. More recently, Sandy has held the dual role of Chief Commercial Officer of DBG Health, and Chief Executive Officer of VidaCorp, the Consumer Health & Beauty division of DBG Health.

-

-

-

-

-